While the fallout from Johnson and Johnson (NYSE: JNJ) decision to shut down Animas continues to reverberate through the insulin pump community the rest of the diabetes world marches on. A march that is increasingly becoming data intensive. Yes, you can’t swing that proverbial dead cat without hitting this obsession with data. An obsession that has only become more intense after the FreeStyle Libre was approved by the FDA.
Although we have known for some time that CGM would replace BGM as the standard for glucose measurement it seems now that Libre has been approved the rest of the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.